Author + information
- Received February 28, 1994
- Revision received May 31, 1994
- Accepted July 13, 1994
- Published online December 1, 1994.
- Yangsoo Jang, MD, PhD,
- A.Michael Lincoff, MD, FACC,
- Edward F. Plow, PhD and
- Eric J. Topol, MD, FACC∗
- ↵∗Address for correspondence: Dr. Eric J. Topol, Department of Cardiology, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, Ohio 44195-5066.
To date, six families of cell adhesion molecules are known. These are cell surface receptors that mediate adhesion of cells to each other or to components of the extracellular matrix and include integrins, selecting, the iminunoglobulin superfamily, cadherins, proteoglycans and mucins. These cell adhesion molecules play a key role in cell-cell interaction (such as among endothelium, monecytes, smooth muscle cells and platelets) and cell-extracellular matrix interaction (such as between leukocytes, platelets or fibroblasts and the extracellular matrix). The importance of these interactions has recently been demonstrated in clinical trials with the use of an antibody fragment directed against the platelet αIIbβIIIa integrin, with reduction of arterial thrombosis and restenosis after percutaneous coronary interventions. A fundamental role for cell adhesion molecules bas been suggested for several other relevant disease processes, including atherosclerosis, acute coronary syndromes, reperfusion injury and allograft vasculopathy. This review focuses on providing the clinically relevant biology of these families of adhesion molecules, setting the foundation for delineation of their emerging role in cardiovascular therapeutics.
- Received February 28, 1994.
- Revision received May 31, 1994.
- Accepted July 13, 1994.